Feed AZTA
AZ

Azenta, Inc.

AZTA · NASDAQ

$32.04 +3.76% (+$1.16)
1M -4.59%
Market Cap $1.48B
P/E Ratio -
Div. Yield -
ROE 7.56%

Bulios Fair Price

$19.21

40.0% downside

Current Price

$32.04

Undervalued Fair Value Overvalued

According to Bulios Fair Price, AZTA is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
37 /100
Fair
P/FCF 149.46x
P/S 2.41x
P/B 0.98x
Growth
24 /100
Declining
Book val. growth 19.92%
Rev. growth 2.25%
FCF growth N/A
Profitability
22 /100
Weak
Op. margin 3.49%
Gross margin 44.05%
FCF margin 1.61%
Quality
4 /100
Poor
ROA 6.55%
ROIC 0.98%
Asset turnover 0.33x
Debt
100 /100
Low
Current ratio 2.50x
Debt/Equity 0.04x
Debt/Assets N/A
Stability
31 /100
Unstable
EPS volatility 759.07%
Beta 1.39x
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about AZTA
Online

About the company

Azenta, Inc. is an American technology and biotechnology company specializing in providing solutions for life sciences, including services focused on genomics, biotechnology research, and laboratory automation. The company offers a wide range of products and services that help researchers and organizations accelerate the development of new therapies and medications. Azenta is known for its advanced technology in biological sample storage, logistics, and genetic research, contributing to more efficient research in the field of biomedicine.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Martin D. Madaus

Employees

2,900

Headquarters

Burlington

Upcoming events

20 NOV

Earnings

Upcoming earnings report

66d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.